navenibart Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: June 2, 2026

The clinical evidence base for navenibart comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Angioedema. Most recent publication: Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema., J Allergy Clin Immunol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
Banerji A, Craig T, Sitz K, et al. · J Allergy Clin Immunol · 2026
PubMed: PMID 41794053 · NCT05695248 · Angioedema

Publications by year

2026–2026: 1 publications.

2026

Publications by indication

Angioedema (1)

Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
J Allergy Clin Immunol · 2026 · PMID 41794053 · NCT05695248

Publications by journal

J Allergy Clin Immunol1 paper

All navenibart publications (1)

2026 (1 paper)

Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
Banerji A, Craig T, Sitz K, et al. · J Allergy Clin Immunol · 2026 · Trial result
PubMed: PMID 41794053 · NCT05695248 · Angioedema

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 02 Jun 2026 17:36:55 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).